Mary Wilson
New member
September 23, 2020 at 5:45 a.m. CDT
By Carolyn Y. Johnson
The first coronavirus vaccine that aims to protect people with a single shot has entered the final stages of testing in the United States in an international trial that will recruit up to 60,000 participants.
The experimental vaccine being developed by pharmaceutical giant Johnson & Johnson is the fourth vaccine to enter the large, Phase 3 trials in the United States that will determine whether they are effective and safe. Paul Stoffels, chief scientific officer of J&J, predicted that there may be enough data to have results by the end of the year and said the company plans to manufacture 1 billion doses next year.
https://www.washingtonpost.com/health/2020/09/23/coronavirus-vaccine-jj-single-shot/
By Carolyn Y. Johnson
The first coronavirus vaccine that aims to protect people with a single shot has entered the final stages of testing in the United States in an international trial that will recruit up to 60,000 participants.
The experimental vaccine being developed by pharmaceutical giant Johnson & Johnson is the fourth vaccine to enter the large, Phase 3 trials in the United States that will determine whether they are effective and safe. Paul Stoffels, chief scientific officer of J&J, predicted that there may be enough data to have results by the end of the year and said the company plans to manufacture 1 billion doses next year.
https://www.washingtonpost.com/health/2020/09/23/coronavirus-vaccine-jj-single-shot/
